Sarepta Therapeutics, Inc. EPS (Earnings per Share) 2009–2025
Sarepta Therapeutics, Inc. reported $-7.13 of earnings per share for fiscal 2025. That was 404.7% lower than fiscal 2024. Compared with fiscal 2020, the change was -0.3%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $-7.13 | -404.7% |
| FY 2024 | $2.34 | +140.3% |
| FY 2023 | $-5.80 | +27.8% |
| FY 2022 | $-8.03 | -55.9% |
| FY 2021 | $-5.15 | +27.6% |
| FY 2020 | $-7.11 | — |
| FY 2019 | $0.00 | — |
| FY 2018 | $0.00 | — |
| FY 2017 | $0.00 | — |
| FY 2016 | $0.00 | — |
| FY 2015 | $0.00 | — |
| FY 2014 | $0.00 | — |
| FY 2013 | $0.00 | — |
| FY 2012 | $0.00 | +100.0% |
| FY 2011 | $-0.12 | +93.1% |
| FY 2010 | $-1.74 | -7.4% |
| FY 2009 | $-1.62 | — |
Source: Sarepta Therapeutics, Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SRPT 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Sarepta Therapeutics, Inc. reported $-7.13 of earnings per share for fiscal 2025. That was 404.7% lower than fiscal 2024. Compared with fiscal 2020, the change was -0.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Sarepta Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSarepta Therapeutics, Inc. — frequently asked questions
What is Sarepta Therapeutics, Inc.'s earnings per share?
Sarepta Therapeutics, Inc. (SRPT) reported earnings per share of $-7.13 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Sarepta Therapeutics, Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.